Citations (27)
Keep up to date with the latest research on this topic with citation updates for this article.
Articles from other publishers (27)
Yifan Luo, Chao Li, Yiwen Zhang, Peixin Liu, Hongyi Chen, Zhenhao Zhao, Yu Wang, Zheng Zhou, Haolin Song, Boyu Su, Chufeng Li, Xuwen Li, Tongyu Zhang, Haoyu You, Yuxing Wu, Zonghua Tian, Shilin Zhang, Yun Guo, Hongrui Fan, Qinjun Chen, Chen Jiang & Tao Sun. (2023) Gradient tumor microenvironment-promoted penetrating micelles for hypoxia relief and immunosuppression reversion in pancreatic cancer treatment. Acta Biomaterialia 167, pages 387-400.
Crossref
Crossref
Huaqing Shi, Zhou Chen, Shi Dong, Ru He, Yan Du, Zishun Qin & Wence Zhou. (2022) A nomogram for predicting survival in patients with advanced (stage III/IV) pancreatic body tail cancer: a SEER-based study. BMC Gastroenterology 22:1.
Crossref
Crossref
Surya K. De. 2022. Fundamentals of Cancer Detection, Treatment, and Prevention. Fundamentals of Cancer Detection, Treatment, and Prevention
341
353
.
Shrey Modi, Bhuwan Giri, Vineet K. Gupta, Shweta Lavania, Vrishketan Sethi, Nikita S. Sharma, Somnath Pandey, Selwyn Vickers, Vikas Dudeja & Ashok K. Saluja. (2022) Minnelide synergizes with conventional chemotherapy by targeting both cancer and associated stroma components in pancreatic cancer. Cancer Letters 537, pages 215591.
Crossref
Crossref
Binglin Sui, Chen Cheng, Shanshan Shi, Mingming Wang & Peisheng Xu. (2021) Esterase‐Activatable and Glutathione‐Responsive Triptolide Nano‐Prodrug for the Eradication of Pancreatic Cancer. Advanced NanoBiomed Research 1:11, pages 2100040.
Crossref
Crossref
Salah‐Eddin Al‐Batran, Ralf‐Dieter Hofheinz, Alexander Reichart, Claudia Pauligk, Caroline Schönherr, Rudolf Schlag, Gabriele Siegler, Steffen Dörfel, Michael Koenigsmann, Mark‐Oliver Zahn, Jörg Schubert, Ali Aldaoud, Heinz‐Gert Höffkes, Holger Schulz, Lars Hahn, Jens Uhlig, Wolfgang Blau, Martina Stauch, Jörg Weniger, Martin Wolf, Lutz Jacobasch, Stephan Bildat, Jürgen Wehmeyer, Nils Homann, Jörg Trojan, Oliver Waidmann, Thomas Fietz, Hans‐Peter Feustel, Matthias Groschek, Jan Wierecky, Karin Waibel, Stefan Mahlmann, Uwe Schwindel, Uwe Peters, Gunter Schuch, Daniel Pink, Henning Eschenburg, Marcus‐A. Wörns, Hans‐Detlev Harich, Ludwig Fischer Weikersthal, Klaus‐Ulrich Däßler, Dirk M. Behringer, Helmut Messmann, Albrecht Kretzschmar, Eike Gallmeier, Helmut Forstbauer, Volker Kunzmann, Jens Papke, Petra Büchner‐Steudel, Ursula Vehling‐Kaiser, Christoph Springfeld, Arndt Vogel, Thomas J. Ettrich, Marina Schaaf, Gerrit zur Hausen & Thorsten Oliver Götze. (2020)
Quality of life and outcome of patients with metastatic pancreatic cancer receiving first‐line chemotherapy with nab‐paclitaxel and gemcitabine: Real‐life results from the prospective
QOLIXANE
trial of the Platform for Outcome, Quality of Life and Translational Research on Pancreatic Cancer registry
. International Journal of Cancer 148:6, pages 1478-1488.
Crossref
Crossref
Chaoxiong Zhang, Lei Huang, Jingyuan Xiong, Linshen Xie, Shi Ying, You Jia, Yuqin Yao, Xuejiao Song, Zhenguo Zeng & Jialing Yuan. (2021) Isoalantolactone inhibits pancreatic cancer proliferation by regulation of PI3K and Wnt signal pathway. PLOS ONE 16:3, pages e0247752.
Crossref
Crossref
Bolun Jiang, Li Zhou, Jun Lu, Yizhi Wang, Chengxi Liu, Lei You & Junchao Guo. (2020) Stroma-Targeting Therapy in Pancreatic Cancer: One Coin With Two Sides?. Frontiers in Oncology 10.
Crossref
Crossref
Ahmed F. Salem, Luca Gambini, Parima Udompholkul, Carlo Baggio & Maurizio Pellecchia. (2020) Therapeutic Targeting of Pancreatic Cancer via EphA2 Dimeric Agonistic Agents. Pharmaceuticals 13:5, pages 90.
Crossref
Crossref
Keke Nie, Ling Zhang, Yunhong You, Hongmei Li, Xiuhui Guo, Zhongfa Zhang, Chunling Zhang & Youxin Ji. (2020) Irinotecan combined with oxaliplatin and S-1 in patients with metastatic pancreatic adenocarcinoma: a single-arm, three-centre, prospective study. Therapeutic Advances in Medical Oncology 12, pages 175883592097084.
Crossref
Crossref
Takashi Kaneko, Kazuya Sugimori, Yuichiro Tozuka, Taito Fukushima, Kazuya Okada, Hiroyuki Oka, Hiroshi Okazaki & Shin Maeda. (2019) Combination chemotherapy with gemcitabine and nab-paclitaxel for a metastatic pancreatic ductal adenocarcinoma patient undergoing hemodialysis. Clinical Journal of Gastroenterology 12:5, pages 484-489.
Crossref
Crossref
Marika Musielak, Igor Piotrowski & Wiktoria M. Suchorska. (2019) Superparamagnetic iron oxide nanoparticles (SPIONs) as a multifunctional tool in various cancer therapies. Reports of Practical Oncology & Radiotherapy 24:4, pages 307-314.
Crossref
Crossref
Ayhan Ulusakarya, Nahla Teyar, Abdoulaye Karaboué, Mazen Haydar, Sarra Krimi, Pamela Biondani, Yusuf Gumus, Amale Chebib, Wathek Almohamad & Jean-François Morère. (2019) Patient-tailored FOLFIRINOX as first line treatment of patients with advanced pancreatic adenocarcinoma. Medicine 98:16, pages e15341.
Crossref
Crossref
Xin Zhang, Dong Ren, Xianqiu Wu, Xi Lin, Liping Ye, Chuyong Lin, Shu Wu, Jinrong Zhu, Xinsheng Peng & Libing Song. (2018) miR-1266 Contributes to Pancreatic Cancer Progression and Chemoresistance by the STAT3 and NF-κB Signaling Pathways. Molecular Therapy - Nucleic Acids 11, pages 142-158.
Crossref
Crossref
Kazunori Yoh, Hiroki Nishikawa, Hirayuki Enomoto, Noriko Ishii, Yoshinori Iwata, Akio Ishii, Yukihisa Yuri, Yuho Miyamoto, Kunihiro Hasegawa, Chikage Nakano, Ryo Takata, Takashi Nishimura, Nobuhiro Aizawa, Yoshiyuki Sakai, Naoto Ikeda, Tomoyuki Takashima, Hiroko Iijima & Shuhei Nishiguchi. (2018) Implication of exercise interventions on sleep disturbance in patients with pancreatic cancer: a study protocol for a randomised controlled trial. BMJ Open Gastroenterology 5:1, pages e000196.
Crossref
Crossref
Kazunori Yoh, Hiroki Nishikawa, Hirayuki Enomoto, Noriko Ishii, Yoshinori Iwata, Akio Ishii, Yukihisa Yuri, Yuho Miyamoto, Kunihiro Hasegawa, Chikage Nakano, Ryo Takata, Takashi Nishimura, Nobuhiro Aizawa, Yoshiyuki Sakai, Naoto Ikeda, Tomoyuki Takashima, Hiroko Iijima & Shuhei Nishiguchi. (2018) Effect of exercise therapy on sarcopenia in pancreatic cancer: a study protocol for a randomised controlled trial. BMJ Open Gastroenterology 5:1, pages e000194.
Crossref
Crossref
Rong-Tao Zhou, Mei He, Ze Yu, Yang Liang, Yuzhe Nie, Sheng Tai & Chun-Bo Teng. (2017) Baicalein inhibits pancreatic cancer cell proliferation and invasion via suppression of NEDD9 expression and its downstream Akt and ERK signaling pathways. Oncotarget 8:34, pages 56351-56363.
Crossref
Crossref
Janaiah Kota, Julie Hancock, Jason Kwon & Murray Korc. (2017) Pancreatic cancer: Stroma and its current and emerging targeted therapies. Cancer Letters 391, pages 38-49.
Crossref
Crossref
Guido Giordano, Massimo Pancione, Nunzio Olivieri, Pietro Parcesepe, Marianna Velocci, Tania Di Raimo, Luigi Coppola, Giuseppe Toffoli & Mario Rosario D’Andrea. (2017) Nano albumin bound-paclitaxel in pancreatic cancer: Current evidences and future directions. World Journal of Gastroenterology 23:32, pages 5875.
Crossref
Crossref
Steffen Ormanns, Michael Haas, Sibylle Baechmann, Annelore Altendorf-Hofmann, Anna Remold, Detlef Quietzsch, Michael R Clemens, Martin Bentz, Michael Geissler, Helmut Lambertz, Stephan Kruger, Thomas Kirchner, Volker Heinemann & Stefan Boeck. (2016) Impact of SPARC expression on outcome in patients with advanced pancreatic cancer not receiving nab-paclitaxel: a pooled analysis from prospective clinical and translational trials. British Journal of Cancer 115:12, pages 1520-1529.
Crossref
Crossref
Hee-Sheung Lee, Nicholas C.O. Lee, Natalay Kouprina, Jung-Hyun Kim, Alex Kagansky, Susan Bates, Jane B. Trepel, Yves Pommier, Dan Sackett & Vladimir Larionov. (2016) Effects of Anticancer Drugs on Chromosome Instability and New Clinical Implications for Tumor-Suppressing Therapies. Cancer Research 76:4, pages 902-911.
Crossref
Crossref
Walid L. Shaib, Andrew Ip, Kenneth Cardona, Olatunji B. Alese, Shishir K. Maithel, David Kooby, Jerome Landry & Bassel F. El-Rayes. (2016) Contemporary Management of Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer. The Oncologist 21:2, pages 178-187.
Crossref
Crossref
Tasuku Matsuoka. (2016) Molecular targets for the treatment of pancreatic cancer: Clinical and experimental studies. World Journal of Gastroenterology 22:2, pages 776.
Crossref
Crossref
Ya-Ju Hsieh, Sung-Pin Tseng, Yu-Hsuan Kuo, Tain-Lu Cheng, Chiao-Yu Chiang, Yew-Min Tzeng & Wan-Chi Tsai. (2016)
Ovatodiolide of
Anisomeles indica
Exerts the Anticancer Potential on Pancreatic Cancer Cell Lines through STAT3 and NF-
κ
B Regulation
. Evidence-Based Complementary and Alternative Medicine 2016, pages 1-10.
Crossref
Crossref
Stephan A Ohnmacht, Chiara Marchetti, Mekala Gunaratnam, Rachael J Besser, Shozeb M Haider, Gloria Di Vita, Helen L Lowe, Maria Mellinas-Gomez, Seckou Diocou, Mathew Robson, Jiri Šponer, Barira Islam, R Barbara Pedley, John A Hartley & Stephen Neidle. (2015) A G-quadruplex-binding compound showing anti-tumour activity in an in vivo model for pancreatic cancer. Scientific Reports 5:1.
Crossref
Crossref
Dacheng Xie & Keping Xie. (2015) Pancreatic cancer stromal biology and therapy. Genes & Diseases 2:2, pages 133-143.
Crossref
Crossref
Brian T. DeCant, Daniel R. Principe, Carmen Guerra, Marina Pasca di Magliano & Paul J. Grippo. (2014) Utilizing past and present mouse systems to engineer more relevant pancreatic cancer models. Frontiers in Physiology 5.
Crossref
Crossref